

Studies Relevant to Long-Term Outcomes of Psychiatric Drugs

1. Longitudinal Studies

a. Harrow

- i. Harrow, M., Jobe, T. H., & Faull, R. N. (2012). **Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.** *Psychological Medicine*, 42(10), 2145-2155.
- ii. Harrow, M., & Jobe, T. H. (2013). **Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?** *Schizophrenia Bulletin*, 39(5), 962-965.

b. Wunderink

- i. Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013). **Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy.** *JAMA Psychiatry*, 70(9), 913.
- ii. Steingard, S. (2013). **Why Wunderink Matters.** *Community Psychiatrist*, 27(2), 2-3.

c. Vermont Longitudinal Study

- i. Harding, C. M., Brooks, G. W., Ashikaga, T., Strauss, J., & Breier, A. (1987). **The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia.** *American Journal of Psychiatry*, 144(6), 727-735.
- ii. Harding, C. M., & Zahniser, J. H. (1994). **Empirical correction of seven myths about schizophrenia with implications for treatment.** *Acta Psychiatrica Scandinavica*, 90(S384), 140-146.

d. Pre-thorazine vs. Post thorazine comparison

- i. Bockoven, J., & Solomon, H. (1975). **Comparison of two five-year follow-up studies: 1948 to 1952 and 1967 to 1972.** *American Journal of Psychiatry*, 132(8), 796-801.

e. WHO studies

- i. Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., . . . Bertelsen, A. (1992). **Schizophrenia: Manifestations, incidence and course in different cultures A World Health Organization Ten-Country Study.** *Psychological Medicine. Monograph Supplement*, 20, 1.

- ii. Leff, J., Sartorius, N., Jablensky, A., Anker, M., Korten, A., Gulbinat, W., & Ernberg, G. (1990). **The International Pilot Study of Schizophrenia: Five-Year Follow-Up Findings.** *Psychological Medicine*, 22, 131-144.

2. Iatrogenic harm

a. Macaque Monkey MRI study

- i. Dorph-Petersen, K., Pierri, J. N., Perel, J. M., Sun, Z., Sampson, A. R., & Lewis, D. A. (2005). **The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys.** *Neuropsychopharmacology*, 30(9), 1649-1661.

b. Human MRI studies

- i. Ho, B., Andreasen, N. C., Nopoulos, P., Arndt, S., Magnotta, V., & Flaum, M. (2003). **Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome.** *Archives of General Psychiatry*, 60(6), 585.
- ii. Ho, B., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). **Long-term Antipsychotic Treatment and Brain Volumes.** *Archives of General Psychiatry*, 68(2), 128.
- iii. Chakos, M., Lieberman, J., Bilder, R., Borenstein, M., G. L., Bogarts, B., . . . Ashtari, M. (1994). **Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.** *American Journal of Psychiatry*, 151(10), 1430-1436.
- iv. Madsen, A., Keiding, N., Karle, A., Esbjerg, S., Hemmingsen, R., & Madsen, A. (1998). **Neuroleptics in progressive structural brain abnormalities in psychiatric illness.** *The Lancet*, 352(9130), 784-785.
- v. Gur, R. E., Maany, V., Mozley, P. D., Swanson, C., Bilker, W., & Gur, R. C. (1998). **Subcortical MRI Volumes in Neuroleptic-Naive and Treated Patients With Schizophrenia.** *American Journal of Psychiatry*, 155(12), 1711-1717.
- vi. Gur, R. E., Cowell, P., Turetsky, B. I., Gallacher, F., Cannon, T., Bilker, W., & Gur, R. C. (1998). **A Follow-up Magnetic Resonance Imaging Study of Schizophrenia.** *Archives of General Psychiatry*, 55(2), 145.

c. Dopamine Supersensitivity

- i. Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., . . . Talletico, T. (2005). **Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.** *Proceedings of the National Academy of Sciences*, 102(9), 3513-3518.
- ii. Samaha, A., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007). **"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time.** *Journal of Neuroscience*, 27(11), 2979-2986.

- iii. Muller, P., & Seeman, P. (1978). **Dopaminergic supersensitivity after neuroleptics: Time-course and specificity.** *Psychopharmacology*, 60(1), 1-11.
 - iv. Chouinard, G., & Jones, B. (1980). **Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics.** *American Journal of Psychiatry* AJP, 137(1), 16-21.
 - d. Anti-depressants increasing chronicity and poor outcomes
 - i. Van Scheyen, J. (1973). **Recurrent vital depressions.** *Psychiatry, Neurologia, Neurochirurgia*, 76, 93-112.
 - ii. Shea, M. (1992). **Course of depressive symptoms over followup.** *Archives of General Psychiatry*, 49, 782-87.
 - e. Meta-analysis
 - i. Radua, J., Borgwardt, S., Crescini, A., Mataix-Cols, D., Meyer-Lindenberg, A., McGuire, P., & Fusar-Poli, P. (2012). **Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication.** *Neuroscience & Biobehavioral Reviews*, 36(10), 2325-2333.
 - f. Tardive dyskinesia and global decline
 - i. Crane, G. E. (1968). **Tardive Dyskinesia in Patients Treated with Major Neuroleptics: A Review of the Literature.** *American Journal of Psychiatry*, 124(8S), 40-48.
 - ii. Perris, C., Dimitrijevic, P., Jacobsson, L., Paulsson, P., Rapp, W., & Froberg, H. (1979). **Tardive dyskinesia in psychiatric patients treated with neuroleptics.** *The British Journal of Psychiatry*, 135(6), 509-514.
- 3. Alternative/experimental treatment models
 - a. Open Dialogue
 - i. Seikkula, J., Aaltonen, J., Alakare, B., Haarakangas, K., Keränen, J., & Lehtinen, K. (2006). **Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies.** *Psychotherapy Research*, 16(2), 214-228.
 - b. Soteria
 - i. Mosher, L. R., Vallone, R., & Menn, A. (1995). **The Treatment of Acute Psychosis Without Neuroleptics: Six-Week Psychopathology Outcome Data From the Soteria Project.** *International Journal of Social Psychiatry*, 41(3), 157-173.
 - ii. Matthews, S. M., Roper, M. T., Mosher, L. R., & Menn, A. Z. (1979). **A Non-neuroleptic Treatment for Schizophrenia: Analysis of the Two-year Postdischarge Risk of Relapse.** *Schizophrenia Bulletin*, 5(2), 322-333.

- iii. Bola, J. R., & Mosher, L. R. (2003). **Treatment of Acute Psychosis Without Neuroleptics: Two-Year Outcomes From the Soteria Project.** *The Journal of Nervous and Mental Disease*, 191(4), 219-229.
 - c. NIMH studies with non-medicated patients
 - i. Carpenter, W. T., Jr., McGlashan, T. M., & Strauss, J. S. (1977). **The treatment of acute schizophrenia without drugs: An investigation of some current assumptions.** *American Journal of Psychiatry*, 134(1), 14-20.
 - ii. Rappaport, M. (1978) **Are there schizophrenics for whom drugs may be unnecessary or contraindicated?** *Int Pharmacopsychiatry*, 13, 100-11.
- 4. Discontinuation studies
 - a. Prien, R. F., Cole, J. O., & Belkin, N. F. (1969). **Relapse in Chronic Schizophrenics following Abrupt Withdrawal of Tranquilizing Medication.** *The British Journal of Psychiatry*, 115(523), 679-686.
 - b. Prien, R. F., Levine, J., & Switalski, R. W. (1971). **Discontinuation of Chemotherapy for Chronic Schizophrenics.** *Psychiatric Services*, 22(1), 4-7.
 - c. Power, K. G., Jerrom, D. W., Simpson, R. J., & Mitchell, M. (1985). **Controlled study of withdrawal symptoms and rebound anxiety after six week course of diazepam for generalised anxiety.** *British Medical Journal*, 290(6477), 1246-1248.
 - d. Ballenger, C. (1988) **Alprazolam in panic disorder and agoraphobia.** *Archives of General Psychiatry* 45, 413-22.
- 5. Other
 - a. Schooler, N. R., Goldberg, S. C., Boothe, H., & Cole, J. O. (1967). **One Year After Discharge: Community Adjustment of Schizophrenic Patients.** *American Journal of Psychiatry*, 123(8), 986-995.
 - b. Hegarty, J. D., Baldessarini, R. J., M. T., Waternaux, C., & G. O. (1994). **One hundred years of schizophrenia: A meta-analysis of the outcome literature.** *American Journal of Psychiatry*, 151(10), 1409-1416.
 - c. Cole, J. (1977). **Maintenance Antipsychotic Therapy.** *American Journal of Psychiatry*, 132, 32-6.
 - d. Aldridge, M. A. (2011). **Addressing non-adherence to antipsychotic medication: A harm-reduction approach.** *Journal of Psychiatric and Mental Health Nursing*, 19(1), 85-96.
 - e. McGlashan, T. (2005). **Schizophrenia in Translation: Is Active Psychosis Neurotoxic?** *Schizophrenia Bulletin*, 32(4), 609-613.